News | Hypertension | December 27, 2018

Barbershop Intervention Continues to Lower Blood Pressure at One Year

Reductions in systolic blood pressure observed at 6 months in Cedars-Sinai study were sustained at 12 months

Barbershop Intervention Continues to Lower Blood Pressure at One Year

December 27, 2018 — African-American men participating in a blood pressure reduction program implemented in barbershops continued to have significant improvements in their blood pressure in a twelve-month follow-up study. The research was published in the American Heart Association journal Circulation.1

In the study led by Cedars-Sinai’s Smidt Heart Institute, 52 Los Angeles County barbershops were assigned to either a pharmacist-led intervention or an active control group. In the intervention group, barbers measured blood pressure and promoted follow-up with pharmacists who prescribed blood pressure medication under a collaborative practice agreement with study participants’ primary care providers. In the control group, barbers measured blood pressure and promoted follow-up only with primary care providers and lifestyle modification. At 6 months, the men in the intervention group had significant reductions in their blood pressure compared to those in the control group.

Read the article "Managing Blood Pressure in Barbershops Yields Substantial Improvements" 

After six months, the intervention group continued the program, but had fewer in-person pharmacist visits to test if the intervention effect could be sustained safely for one year while reducing pharmacist travel time to and from barbershops.

When the study began, participants had an average systolic blood pressure of 152.4 mm Hg in the intervention group and 154.6 mm Hg in the control group. Systolic blood pressure is the top number in a blood pressure reading and it measures the pressure the blood exerts against the arteries while the heart is pumping.

At 12 months, the average systolic blood pressure fell by 28.6 mm Hg (to 123.8 mm Hg) in the intervention group and by 7.2 mm Hg (to 147.4 mm Hg) in the control group. The average reduction was 20.8 mm Hg greater with the intervention. These results are indistinguishable from the previously reported 6-month data, which were published in the New England Journal of Medicine.2

The principal investigator for the study was the late Ronald G. Victor, M.D., associate director of the Smidt Heart Institute. In 2010, Victor became the first to prove, through randomized, controlled testing, that barbershop-based health programs could potentially save hundreds of lives annually by helping African American men lower their blood pressure.

Watch the VIDEO: Reducing Hypertension Among African-Americans

For more information: www.ahajournals.org/journal/circ

References

1. Victor R.G., Blyler C.A., Li N., et al. Sustainability of Blood Pressure Reduction in Black Barbershops. Circulation, Dec. 17, 2018. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.038165

2. Victor R.G., Lynch K., Li N., et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. New England Journal of Medicine, April 5, 2018. DOI: 10.1056/NEJMoa1717250


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now